Altamira Therapeutics Ltd

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the following geographical segments: United States, Switzerland, Europe, and Australia. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the Switzerland and Australia geographical segments. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Covadonga Pañeda, Ph.D., to join leadership team as Chief Development Officer for RNA therapeutics Receipt of NIH grant to help advance siRNA delivery platform for use in extrahepatic inflammatory disorders HAMILTON, BERMUDA / ACCESSWIRE / January 13, 2022 / Altamira Therapeutics Ltd.

Altamira Therapeutics Provides Update on RNA Therapeutics Program

HAMILTON, BERMUDA / ACCESSWIRE / January 5, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its Chairman and CEO, Thomas Meyer, will present at the H.C.

Altamira Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference

Yamana Gold

New Gold

Which penny stocks are on your 2022 watchlist? The post Best Penny Stocks to Add to Your New Years Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Add to Your New Years Watchlist

Bentrio™ becoming available through Amazon platform in key German market Definite Marketing and Distribution Agreement signed for six Asian countries Preparations for COVID-19 trial advancing Company to also test effectiveness against Omicron variant HAMILTON, BERMUDA / ACCESSWIRE / December 29, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today provided a business update on Bentrio™, its nasal spray for protection against airborne viruses and allergens.

Altamira Therapeutics Provides Update on Bentrio Program

HAMILTON, BERMUDA / ACCESSWIRE / December 16, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that the first group of patients has been randomized in a clinical trial with Bentrio™ (AM-301) in house dust mite ("HDM") allergic rhinitis.

Altamira Therapeutics Announces Randomization of First Patients in Bentrio Trial in House Dust Mite Allergy

HAMILTON, BERMUDA / ACCESSWIRE / December 1, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that the first patient has been randomized in its "NASAR" trial for the clinical evaluation of Bentrio™ (AM-301) in seasonal allergic rhinitis ("SAR").

Altamira Therapeutics Announces Randomization of First Patient in Bentrio Trial in Seasonal Allergic Rhinitis

Farmmi

Moving Image Technologies

Check these penny stocks out for your list this week The post Here's 3 Penny Stocks You Need to Know About Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Here's 3 Penny Stocks You Need to Know About Right Now

Altamira's peptide-based platform for extrahepatic RNA delivery shows promising results in management of abdominal aortic aneurysm in murine disease models siRNA polyplexes targeting NF-kB suppress disease progression and prevent rupture of aorta mRNA polyplexes targeting SOD-2 mitigate expansion of aortic aneurysm HAMILTON, BERMUDA / ACCESSWIRE / November 15, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the presentation of data from two studies by a research group at Washington University, St. Louis, MO, on the use of the Company's RNA delivery platforms for extrahepatic nucleotide delivery in the treatment of abdominal aortic aneurysm ("AAA") at the American Heart Association ("AHA") Scientific Sessions, taking place on November 13-15, 2021.

Altamira Therapeutics Announces Poster Presentations at AHA Scientific Sessions 2021

Sino-Global Shipping America

Can these trending penny stocks continue to make moves in the market? The post 3 Trending Penny Stocks to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Trending Penny Stocks to Watch Right Now

Bit Brother Ltd

Phunware Inc

RLX Technology

SNDL Inc.

Today, a range of penny stocks are surging on various news items amid broader market enthusiasm and a risk-on mindset from traders. The post 6 Top Penny Stocks to Watch Today: SNDL, CYTO, BTB, MITQ, PHUN, RLX appeared first on InvestorPlace.

6 Top Penny Stocks to Watch Today: SNDL, CYTO, BTB, MITQ, PHUN, RLX

Altamira Therapeutics (CYTO) stock is rocketing higher on Friday following the release of positive results from a nasal spray test. The post CYTO Stock: The Nasal Spray News Blowing Altamira Therapeutics Sky-High Today appeared first on InvestorPlace.

CYTO Stock: The Nasal Spray News Blowing Altamira Therapeutics Sky-High Today

The stock price of Altamira Therapeutics Ltd (NASDAQ: CYTO) increased by over 80% during intraday trading. This is why it happened.

Altamira Therapeutics (CYTO) Stock: Why The Price Surged Today

Significant reduction of infectious viral titer in human nasal epithelium model with either prophylactic or therapeutic application Results provide further confirmation for broad applicability in viral infections HAMILTON, BERMUDA / ACCESSWIRE / November 12, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, announced today positive efficacy data from testing its Bentrio™ nasal spray in vitro against the Delta variant of the SARS-CoV-2 virus.

Altamira Therapeutics Reports Positive In vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Delta Variant

The stock price of Altamira Therapeutics Ltd. (NASDAQ: CYTO) by over 10% during intraday trading today.

CYTO Stock: Why It Increased Today

HAMILTON, BERMUDA / ACCESSWIRE / October 14, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its 510(k) application for premarket clearance filed with the U.S. Food and Drug Administration ("FDA") for its Bentrio™ nasal spray for protection against airborne allergens has cleared the Agency's acceptance review.

Altamira Therapeutics Receives FDA Acceptance for Bentrio 510(k) Application

HAMILTON, BERMUDA / ACCESSWIRE / October 6, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that management will participate in A.G.P.

Altamira Therapeutics to Participate in A.G.P.'s Virtual Biotech and Specialty Pharma Conference

HAMILTON, BERMUDA / ACCESSWIRE / September 21, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that it will provide a business update on Bentrio™, its nasal spray for protection against airborne viruses and allergens, through a live conference call and webcast on Monday, September 27, 2021, at 8:00 AM Eastern Time.

Altamira Therapeutics to Provide Business Update on Bentrio(TM) Program

HAMILTON, BERMUDA / ACCESSWIRE / September 9, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its Chairman and CEO, Thomas Meyer, will present at the H.C.

Altamira Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Commercial launch of Bentrio™ nasal spray in first EU markets, with plans to expand to additional European and international markets in the second half of 2021 Enrollment in Phase 2 trial of AM-125 for acute vertigo reached its midpoint in May 2021 and completion is expected in the autumn of 2021 Transformative acquisition of Trasir Therapeutics completed and strategic repositioning around RNA therapeutics well underway HAMILTON, BERMUDA / ACCESSWIRE / September 8, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today provided a business update and announced first half 2021 financial results.

Altamira Therapeutics Provides Business Update and Reports First Half 2021 Financial Results

Sphere 3D

Mustang Bio

Which penny stocks are investors watching this week? Here's 3 for your list The post Are These Penny Stocks Worth Watching This Week?

Are These Penny Stocks Worth Watching This Week? 3 For Your List

Significant reduction of viral titer in human nasal epithelium model both in prevention and treatment of influenza infection (p

Altamira Therapeutics Reports Protective Effects of Bentrio(TM) Nasal Spray Against Influenza A Virus (H1N1)

The stock price of Altamira Therapeutics Ltd (NASDAQ: CYTO) increased by over 25% during intraday trading. This is why it happened.

CYTO Stock Price Increases Over 25% Intraday: Why It Happened

HAMILTON, BERMUDA / ACCESSWIRE / August 3, 2021 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the launch of www.bentrio.com, a website dedicated to the Bentrio™ nasal spray developed by its affiliate Altamira Medica.

News for Altamira Therapeutics Ltd Stock (CYTO)